A new approach to prostate cancer
- 1 July 1989
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 41 (7) , 488-489
- https://doi.org/10.1111/j.2042-7158.1989.tb06507.x
Abstract
Growth of androgen-dependent human prostatic adenocarcinoma implanted in the nude mouse (Honda tumour), is inhibited by 6-methyleneprogesterone. This steroid is a potent inhibitor of both rat and human prostatic 5α-reductase in-vitro. In-vivo, at the studied dose level, it reduces metabolic conversion of testosterone to dihydrotestosterone with minimal effects upon circulating LH and testosterone. These data support the hypothesis that dihydrotestosterone and not testosterone is the main trophic androgen of the human prostatic neoplasm.This publication has 8 references indexed in Scilit:
- Inhibition of 5α-reductase activity in prepubertal female rats: effect on the timing of first ovulationActa Endocrinologica, 1988
- A comparison of the effects of castration and 6-methylene progesterone, a 5α-reductase inhibitor, on the rat ventral prostateBiochemistry and Cell Biology, 1987
- The dihydrotestosterone (DHT) hypothesis of prostate cancer and its therapeutic implicationsThe Prostate, 1986
- HORMONE DEPENDENCY OF A SERIALLY TRANSPLANTABLE HUMAN PROSTATIC-CANCER (HONDA) IN NUDE-MICE1985
- Endocrine dependence of prostatic cancer upon dihydrotestosterone and not upon testosteroneJournal of Pharmacy and Pharmacology, 1984
- Comparative studies of 5α-reductase inhibitors within MCF-7 human breast cancer cellsThe Journal of Steroid Biochemistry and Molecular Biology, 1984
- Inhibitory effects of some steroidal 6-methylene derivatives on 5α-reductase activity in human and rat prostateJournal of Steroid Biochemistry, 1983
- STUDIES ON PROSTATIC CANCERArchives of Surgery, 1941